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von Hippel-Lindau (VHL) disease is an inherited autosomal dominant (AD)
familial cancer syndrome, and hemangioblastomas of the cerebellum and retina,
renal cell carcinoma and pheochromocytoma develop frequently in these patients.
However, glioma and notably astrocytoma have been reported to occur rarely
only in patients with VHL disease and in those without a history of irradiation.
1-3
All previously reported cases of gliomas in patients with VHL disease were low-
grade or pilocytic astrocytomas, whereas malignant glioma, especially gliobla-
stoma multiforme (GBM), has not yet been reported in the literature worldwide.
There has also never been any benign or malignant glioma due to radiation in
patients with VHL disease. Our case involves a 32 year-old male with VHL
disease, and he had multiple cerebellar and spinal hemangioblastomas, pancreatic
cysts and a renal cell carcinoma. The largest hemangioblastoma in his right
cerebellar hemisphere was irradiated with the dose of 50.4 Gy after its complete
excision. It, however, recurred at the same site 7 years later and the cytomor-
phologic features were totally different from those of hemangioblastoma as the
tumor was found to be a malignant glioma, most likely a glioblastoma multi-
forme. Although recurrence and invasion of cerebellar hemangioblastomas have
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We describe herein a malignant glioma arising at the site of the resected hemangioblastoma after irradiation in a
patient with von Hippel-Lindau disease (VHL). The patient was a 25 year-old male with multiple heman-
gioblastomas at the cerebellum and spinal cord, multiple pancreatic cysts and a renal cell carcinoma; he was
diagnosed as having VHL disease. The largest hemangioblastoma at the right cerebellar hemisphere was
completely removed, and he received high-dose irradiation postoperatively. The tumor recurred at the same site 7
years later, which was a malignant glioma with no evidence of hemangioblastoma. The malignant glioma showed
molecular genetic profiles of radiation-induced tumors because of its diffuse p53 immunostaining and the loss of
p16 immunoreactivity. The genetic study to find the loss of heterozygosity (LOH) of VHL gene revealed that only
the cerebellar hemangioblastoma showed allelic losses for the gene. To the best of our knowledge, this report is the
first to show a malignant glioma that developed in a patient with VHL disease after radiation therapy at the site of
an excised hemangioblastoma. This report also suggests that radiation therapy should be performed very carefully
in VHL patients with hemangioblastomas.
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INTRODUCTIONgenerally been reported as their clinical behavior,
4,5 either
malignant transformation of the hemangioblastoma or
radiation-induced malignant glioma in a patient with VHL
disease has not yet been reported in the literature world-
wide. The most common genetic alteration in VHL disease
is known to be allelic loss at chromosome 3p25-26. Most
cases of radiation-induced astrocytomas have been reported
to have p53 mutation.
6 We report herein the first case of
malignant glioma in a patient with VHL disease, and this
tumor developed in the previous excision site of a hemang-
ioblastoma after postoperative irradiation. We also tried to
find the genetic origin of the malignant glioma by examin-
ing the genetic alterations in both the hemangioblastoma
and the malignant recurrent tumor.
Clinical summary
A 25-year-old male first visited our hospital in 1998 with
the chief complaints of headache and dizziness of a remote
onset. He had experienced the symptoms for about 4 years,
but they were aggravated 4 - 5 months before the hospital
visit and they were accompanied with pain on both eye-
balls and bilateral intermittent tinnitus. Magnetic resonance
imaging (MRI) of the brain and cervical spine revealed a 4
×4.5×6 cm-sized cystic tumor with a 2×3 cm-sized
enhancing mural nodule at the right cerebellar hemisphere
(Fig. 1A). The cystic tumor had a heterogeneous rim and
accompanying hydrocephalus. There were also multiple
small enhancing nodules in the left cerebellar hemisphere
and cervical spinal cord. The pancreas and kidney showed
multiple cysts and bilateral cortical simple cysts, respec-
tively. He was diagnosed as having von Hippel-Lindau
disease, based on all these radiographic findings. Under the
impression of hemangioblastoma, he underwent a com-
plete excision of the right cerebellar tumor. One month
after excision, he received a conventional radiotherapy
using 6 megavolume (MV) of photon on both cerebellar
hemispheres and cervical spinal cords, with a total dose of
50.4 Gy being divided by 28 times for 47 days. The
postoperative radiotherapy was performed to treat both the
operated and non-operated multiple hemangioblastomas.
The patient made an uncomplicated recovery for the
excised hemangioblastoma and underwent an uneventful
clinical follow-up for more than 7 years. 
At the age of 32 years in 2005, however, he experienced
headache and dizziness again for about 5 weeks before his
latest visit to the hospital. Brain MRI revealed a big right
cerebellar cystic mass with a total size of 5.8×3.7×3.1
cm. The mass showed heterogeneous and irregular-shaped
enhancement along the thickened walls and the big non-
enhancing necrotic center (Fig. 1B). It was radiologically
suspicious of malignant change, because of the increased
size compared to the previous one, the irregular and
heterogeneous enhancement and the marked peritumoral
edema extending to the contralateral cerebellar hemis-
phere. The right kidney showed a 1.9×1.5×1.3 cm-sized
low-attenuated mass at the upper pole. He underwent two
operations of the right cerebellar mass removal and right
nephrectomy, within an interval of about 2 weeks. The
cerebellar mass, however, was growing very rapidly right
after the second removal to form a big cystic and solid
tumor again with the size of 7.5×5.8×5.0 cm after about
40 days. Brain MRI revealed increased size and extent of
invasion, with diffuse enhancement and peritumoral
edema. The third removal of the cerebellar tumor revealed
the same pathologic findings as the previous recurrent
tumor. When he was 33 years-old in 2006, the right
cerebellar tumor showed two more recurrences at the same
site. He once more underwent excision of the tumor and
then he died after last tumor recurrence.
Pathologic findings
The excised mural nodule of his first right cerebellar tumor
revealed a homogeneously rich cellularity and vascularity
with the main two tumor cell components being stromal
cells and fine capillary networks. The stromal tumor cells
were round to polygonal with foamy abundant cytoplasm,
showing a diffuse immunopositivity for S100 protein (Fig.
2A). The intervening capillaries showed a fine intricate net-
like arrangement, which was delineated better in the CD34
immunostaining (Fig. 2B). Both p53 and glial fibrillary
acidic protein (GFAP) immuno-stainings were negative in
the stromal tumor cells (Fig. 3). All these findings were
compatible with hemangioblastoma.
The recurrent cerebellar tumors had cellularity even
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Fig. 1. Initial brain MRI reveals a 4×4.5×6 cm-sized cystic mass at the right
cerebellar hemisphere with its heterogeneous rim and enhancing mural nodule
(A), and the  newly appeared cerebellar mass at the same site shows a 5.8×3.7
×3.1 cm-sized cystic tumor with a heterogeneous irregular intense enhan-
cement in the thickened walls and non-enhancing necrotic center of irregular
shape (B).
ABhigher than that of the first one, with compactly arranged
polymorphic tumor cell components in the fibrillary stro-
mal background. The tumor cells showed largely short-
spindled to polygonal shapes with eosinophilic granular or
fibrillary cytoplasms, and with marked nuclear atypia and
frequent mitoses, which were compatible with malignant
glioma (Fig. 4A). Many polygonal cells with clear vacuo-
lated cytoplasms were aggregated in large sheets, and they
looked like oligodendroglial cells (Fig. 4B). Some areas
also showed small to medium-sized anaplastic tumor cells
with high nucleocytoplasmic ratio and frequent mitoses
(Fig. 5A). Prominent endothelial proliferation, spotty
necrosis and occasional tumor giant cells were noted (Fig.
5B). Based on all these microscopic findings, these
pleomorphic anaplastic tumor cells could be diagnosed as
a malignant glioma, most likely GBM. Immunohistoche-
mical study revealed diffuse GFAP positivity in the tumor
cells (Fig. 6A). The tumor cells were also highly positive
for p53 immunostaining (Fig. 6B), which is indicative of
p53 mutation. In addition, there was loss of p16 immuno-
reactivity (Fig. 6C), although either epidermal growth
factor receptor (EGFR) overexpression or deletion of
retinoblastoma (RB) gene was not noted. The tumor was
finally diagnosed as malignant glioma, and it was most
likely a glioblastoma multiforme of astrocytic origin. There
was no evidence of any residual hemangioblastoma in the
recurrent tumors. 
Genetic study
We extracted DNA from the cerebellar hemangioblastoma,
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Fig. 2.The initially resected cerebellar mass showed typical histologic findings of
hemangioblastoma, which are characterized by stromal cells with plump foamy
cytoplasms and abundant arborizing capillary networks (A). Immunohisto-
chemically, the capillary endothelial cells were reactive for CD34 primary
antibody (B1) and stromal tumor cells showed diffuse and strong cytoplasmic
immunoreactivity for S100 protein (B2).
AB 2
B1
Fig. 3. Immunohistochemically, the hemangioblastoma cells were negative for
GFAP (A) and have no p53 nuclear immunopositivity (B).
AB
Fig. 4. Microscopically, the recurrent cerebellar glioblastoma was largely
composed of highly cellular round to spindle-shaped pleomorphic tumor cells
with hyperchromatic nuclei and fibrillary cytoplasms, with fibromyxoid
degeneration (A). Oligodendrogliomatous areas were multifocally found, with
prominent endothelial proliferation (B).
AB
Fig. 5. The small cell glioblastoma-like areas showed small to medium-sized
anaplastic tumor cells with high nucleocytoplasmic ratio and brisk mitotic
activity (A). Spotty necroses were occasionally found among the tumor cells (B).
AB
Fig. 6.The malignant glioma revealed diffuse immunoreactivity for both GFAP (A)
and p53 (B), and the diffuse loss of immunopositivity for p16 protein in tumor cells
in comparison to the immunostained benign endothelial cell nuclei (C).
A B Crecurrent malignant gliomas, and renal cell carcinoma from
their paraffin blocks, along each normal tissue counterpart
within the same block. We performed a chromosomal DNA
polymerase chain reaction (PCR) to compare and evaluate
the qualitative change such as an allelic loss among the
tumor and normal groups. Loss of heterozygosity (LOH)
of the initial and recurrent tumors was analyzed with three
microsatellite probes (D3S 1038, D3S 1317, and D3S
1304) for 3p and one polymorphism marker (A1149G) for
the VHL gene.
7 Only the cerebellar hemangioblastoma
showed allelic losses for two genetic loci of 3p25-26 (D3S
1038 and D3S 1304) (Fig. 7). The allelic loss at the genetic
locus detected by D3S 1304 microsatellite probe was more
severe than that by D3S 1038 probe. The malignant glial
tumor and renal cell carcinoma revealed no evidence of
LOH for all four oligonucleotide primers. The results of
the genetic and immunohistochemical studies are sum-
marized in Table 1.
Astrocytomas arising in VHL disease have been reported
mostly as pilocytic and low-grade cerebellar astrocytomas,
which developed as either primary or recurrent tumors in
patients with VHL disease.
1-3 The reported cases had no
history of radiation therapy. However, any malignant glial
neoplasms in VHL disease either by radiation or not have
not yet been reported in the literature worldwide. The
present case displayed a recurrent cerebellar tumor 7 years
after his right cerebellar mass had been excised and then
irradiated with 50.4 Gy of high dose radiation. The recurrent
tumor showed totally different histopathology in com-
parison to the hemangioblastoma, and the recurrent tumor
had a history of high-dose radiation therapy, diffuse GFAP
immunopositivity, p53 mutation and no LOH for the VHL
gene. The recurrent tumor was, therefore, considered to be
Malignant Glioma in VHL Disease after Radiation
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Fig. 7. The cerebellar hemangioblastoma (HBL-T) showed allelic losses detected by 2 microsatellite probes D3S 1038 (A) and D3S 1304 (B) at the
3p25-26 loci (VHL gene) (arrows), whereas the malignant gliomas (GBM-Ta and Tb) revealed retention of heterozygosity. HBL-N, normal control
tissue of hemangioblastoma; HBL-T, hemangioblastoma tumor cells; RCC-N, normal control tissue of renal cell carcinoma; RCC-T, tumor tissue of
renal cell carcinoma; GBM-N, normal tissue of glioblastoma multiforme; GBM-Ta, tumor tissue of GBM at the first recurrence; GBM-Tb, tumor
tissue of GBM at the second recurrence.
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Table 1. The Immunohistochemical and Genetic Profiles of the Cerebellar Hemangioblastoma, Glioblastoma 
and Renal Cell Carcinoma in the Patient with VHL Disease
IHC and genetic studies
Cerebellar 
GBM Renal cell carcinoma
haemangioblastoma
GFAP Negative Positive Negative
p53 mutation Negative Positive Positive
p16 deletion / EGFR exp. Negative Positive / Negative Not done
LOH(D3S1308 & 1304) Yes No No
LOH(D3S1317 & A1149G) No No No
VHL, von Hippel-Lindau; IHC, immunohistochemical; GFAP, glial fibrillary acidic protein; LOH, loss of heterozygosity; GBM,
glioblastoma multiforme; Exp, expression.
DISCUSSIONa radiation-induced malignant glioma rather than malig-
nant transformation of the hemangioblastoma, and it
fulfilled the criteria for the radiation-induced neoplasm.
The criteria for radiation-induced neoplasm are generally
known to be as follows;
8-10 1) the tumor must appear in the
irradiated area, 2) the tumor must not be present prior to
irradiation, 3) a sufficient latency period must elapse
between irradiation and the appearance of the tumor, 4) the
radiation-induced tumor must be histologically proven and
it must be of a different histological type from the original
first tumor that was treated by radiation therapy, 5) the
incidence of second lesions is significantly higher than that
in controls, and 6) there must be no known genetic or other
predisposing conditions for tumor development. The
present case fully met the criteria 1 through 5, but not 6
because he has a genetic basis for VHL disease, which is
known to be an AD tumor-prone syndrome. However, VHL
disease patients have not yet been reported to develop any
benign or malignant tumors after radiation therapy.
11 There-
fore, it is considered that the 6th criteria can be applied
loosely to the radiation-induced tumors in the VHL disease
patients, because they don’t seem to be genetically vulner-
able to the radiation. On the other hand, other AD tumor-
prone conditions such as neurofibromatoses types 1 and 2
have frequently been reported to have benign or malignant
neoplasms like malignant peripheral nerve sheath tumor
(MPNST) that occurred after radiotherapy.
11 It would,
therefore, appear that patients with genetic disorders are
particularly sensitive to radiation carcinogenesis due to
their relative genetic instability.
11 Malignant glioma spon-
taneously arising in a cerebellar hemangioblastoma has not
yet been reported either. Our case didn’t seem to show malig-
nant transformation from the cerebellar hemangiobla-
stoma, as the hemangioblastoma had no GFAP immuno-
positivity and it was grossly completely excised, with no
residual tumor after the first operation and before irradiation.
The carcinogenesis of radiation-induced malignant
gliomas is not clear, but ionizing radiation is well-known
to induce genomic instability, which is transmitted over
many generations through the progeny of the surviving
cells. Since the induced genomic instability accumulates
gene mutations and gross chromosomal rearrangements, it
has been thought to play a role in radiation-induced car-
cinogenesis. It has also been suggested that radiation-
induced neoplasms are caused by imperfect repair of
delayed ionizing radiation-induced DNA strand breaks in
the tumor suppressor genes or the protooncogenes.
6,12,13
Radiation-induced gliomas are generally known to be
high-grade at clinical presentation and they are mostly
astrocytic in their differentiation. Our case showed malig-
nant glioma with diffuse GFAP immunopositivity, there-
fore, could be diagnosed as GBM of an astrocytic origin.
These tumors have also been reported to have genetic
alterations similar to primary spontaneous high-grade
astrocytoma.
6 They include EGFR amplification, p16
deletion and p53 mutation.
6 In the present case, immuno-
histochemical staining showed p53 mutation and p16
deletion in the malignant glioma, although either EGFR
overexpression or RB deletion was not detected. These
genetic alterations of the malignant glioma suggest that it
occurred as a result of radiation-induced genomic instability
of the surviving cerebellar glial cells without the genetic
alteration of VHL disease.
The primary tumors which are known to develop post-
irradiation malignant gliomas have been reported to be
pituitary adenoma, medulloblastoma, retinoblastoma,
malignant lymphoma, acute leukemia, thyroid carcinoma
and meningioma.
8,10,14-16 Cerebellar hemangioblastoma has
never been listed to date in the literature as a primary
tumor that can evoke postirradiation malignancy. However,
we experienced a case of cerebellar hemangioblastoma in
a patient with VHL disease, and the patient developed
malignant glioma after receiving 50.4 Gy of irradiation at
the original complete resection site. This case report
stresses the fact that radiation as an adjuvant therapy of
hemangioblastoma should be used and monitored more
strictly in a patient with VHL disease because a malignant
glioma such as GBM can develop several years later at the
irradiation site. 
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